| Nov 13 |
Oculis to Present at the Stifel 2024 Healthcare Conference
|
| Nov 8 |
Oculis Holding Third Quarter 2024 Earnings: Misses Expectations
|
| Nov 7 |
Oculis Holding GAAP EPS of -$0.48
|
| Nov 7 |
Oculis Reports Q3 2024 Financial Results and Provides Company Updates
|
| Nov 4 |
Oculis: Lack Of Coverage Only Real Risk For This Solid Company
|
| Oct 30 |
Oculis Holding AG's (NASDAQ:OCS) largest shareholders are individual investors with 56% ownership, institutions own 39%
|
| Oct 21 |
Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees
|
| Oct 15 |
Oculis’ DIAMOND Phase 3 Program in Diabetic Macular Edema to be Presented at Innovate Retina and Eyecelerator 2024
|
| Oct 2 |
Oculis Announces Appointment of Daniel S. Char as Chief Legal Officer
|
| Sep 19 |
Oculis and EURETINA Announce the Winner of the Inaugural Ramin Tadayoni Award
|
